Mucin1 (MUC1) is an epithelial glycoprotein overexpressed in ovarian cancer and actively involved in tumor cell migration and metastasis. Using novel in vitro and in vivo MUC1-expressing conditional (Cre-loxP) ovarian tumor models, we focus here on MUC1 biology and the roles of Kras activation and Pten deletion during cell transformation and epithelial-to-mesenchymal transition (EMT). We generated several novel murine ovarian cancer cell lines derived from the ovarian surface epithelia (OSE) of mice with conditional mutations in Kras, Pten or both. In addition, we also generated several tumor-derived new cell lines that reproduce the original tumor phenotype in vivo and mirror late stage metastatic disease. Our results demonstrate that de novo activation of oncogenic Kras does not trigger increased proliferation, cellular transformation or EMT, and prevents MUC1 upregulation. In contrast, Pten deletion accelerates cell proliferation, triggers cellular transformation in vitro and in vivo, and stimulates MUC1 expression. Ovarian tumor-derived cell lines MKP-Liver and MKP-Lung cells reproduce in vivo EMT and represent the first immune competent mouse model for distant hematogenous spread. Whole genome microarray expression analysis using tumor and OSE-derived cell lines reveal a 121 gene signature associated with EMT and metastasis. When applied to n = 542 cases from The Cancer Genome Atlas (TCGA) ovarian cancer dataset, the gene signature identifies a patient subset with decreased survival (P = 0.04). Using an extensive collection of novel murine cell lines we have identified distinct roles for Kras and Pten on MUC1 and EMT in vivo and in vitro. The data has implications for future design of combination therapies targeting Kras mutations, Pten deletions and MUC1 vaccines.
INTRODUCTION
Ovarian cancer is often diagnosed at late stages, when the tumor has spread outside the ovaries. Loco-regional dissemination involves detachment of cancer cells from the primary tumor and attachment on the surface of surrounding anatomical sites, frequently not only on the omentum and peritoneum, but also on the diaphragm and small bowel mesentery. 1, 2 Lung metastases have been reported in up to 12% of patients. [3] [4] [5] As expected, disseminated stage IV ovarian cancer has poor prognosis with 10 year survival rate of only 6%, in contrast to 73-92% in stage I cancer, confined to the ovaries. 2 It is believed that cancer dissemination may be linked, at least in part, to a process called epithelial-to-mesenchymal transition (EMT), during which epithelial tumor cells acquire a fibroblast-like morphology, and display an invasive phenotype and increased proliferation. 6 Although EMT is multifactorial and has been described for several solid tumors, the process has not been captured thus far in ovarian cancer in vivo in immune competent animal models.
We focus here on the pathogenic roles of oncogenic Kras, Pten tumor suppressor and mucin 1 (MUC1) oncoprotein, a cell surface protein with roles in cell adhesion and migration. 7 MUC1 is a transmembrane molecule overexpressed by virtually all ovarian adenocarcinomas, regardless of histology. 8, 9 Although the molecule can present in several isoforms, the major full length MUC1 protein comprises an elongated extracellular region, a transmembrane domain and a cytosolic tail with signaling properties. 10, 11 Given the high density of negatively charged sialic acid residues that cap the branched O-linked glycosylation sites, MUC1 may aid in the initial cell detachment from the primary tumor. 12 In addition, owing to its large extracellular domain, MUC1 may also intermediate subsequent steps, by facilitating adhesion at the metastatic site. 13, 14 The oncogenic function of MUC1 is attributed to its intracellular domain that contains several phosphorylation domains. 15 The links between MUC1 biology and the typical oncogenic or tumor suppressor pathways altered in ovarian cancer have not as yet been addressed.
High-grade serous ovarian tumors are considered to arise mostly from precursor lesions in the fallopian tubes 16 and are overwhelmingly characterized by TP53 mutations, present in 93% of cases. 17 In addition to TP53, ovarian tumors may also carry oncogenic KRAS mutations and PTEN deletion mutations 18 or altered expression, 19 although these type of mutations are more frequent in non-serous tumors, especially endometrioid and clear cell histotypes. PTEN phosphatase acts as a repressor of the oncogenic PI3K pathway, a complex signaling network associated with membrane tyrosine kinase receptors. PTEN deletion occurs in 5% of high-grade serous, 20, 21 20% of clear cell and 20% of endometrioid ovarian cancer patients. 22 Overall, the PI3K/AKT pathway is one of the most significantly deregulated cancer associated pathways in ovarian cancer. 23, 24 Mutations of KRAS and PTEN have been used to model endometrioid ovarian cancer 25 and have been also reported in 24.6 and 77% of endometrioid endometrial tumors, respectively emphasizing the influence of these mutations in gynecologic cancer pathogenesis. 17 Here we generated several new murine ovarian cancer cell lines which express human MUC1gene as self. Using these cell lines, we elucidate the possible roles of Ras/Mek and the Pten/Akt pathways in regulation of MUC1 expression during transformation and EMT in ovarian cancer cells. (Table 1) . Regardless of the originating genetic background, all primary OSE cells were immortalized at similar rates and largely maintained the cobblestone-like, epithelial morphology ( Figure 1a) . To induce the mutations, we exposed the cells to AdCre, which floxes out the loxP sites from either the Kras locus (in MKOSE-AdCre cells), Pten locus (in MPOSE-AdCre) or both (in MKPOSE-AdCre) (Figure 1b) . Activation of oncogenic Kras leads to increased pMek (which acts downstream of Kras) in MKOSE-AdCre cells, as deletion of Pten (which acts as Pi3k inhibitor) increases pAkt expression in MPOSEAdCre cells (Figure 1c ). MKPOSE-AdCre cells with simultaneous Kras activation and Pten deletion have increased levels of both pMek and pAkt (Figure 1c ). Cells exposed to no virus or to empty vector (EV) served as controls.
RESULTS

Kras activation and
Loss of Pten increases mitosis as oncogenic Kras only minimally influences it (Figure 1d and Supplementary Figure 1) . When combined, oncogenic Kras activation and Pten loss exert a synergistic effect on cell proliferation through accelerated mitosis (Figure 1d and Supplementary Fig. 1 ). Growth in soft agar, a measurement of anchorage-independent cell growth and cellular transformation, and ultimately a hallmark of carcinogenesis, 26 shows increased colony formation in cells with Pten deletion alone or in combination with Kras activation. In contrast, cells with Kras activation alone were unable to form any colonies (Figure 1e ). In line with findings from growth in soft agar, all the mice injected with MPOSE-AdCre (n = 6) and MKPOSE-AdCre (n = 7) developed tumors ( Figure 1f ). However, none of the mice injected with MKOSE-AdCre cells (n = 5), showed any signs of disease and had no macroscopic tumors at necropsy, performed 8 weeks post tumor challenge.
In addition to proliferation and transformation, we also assessed EMT induction in cells with active oncogenic Kras, Pten deletion or both. MKOSE-AdCre and MPOSE-AdCre cells, cultured in vitro for the same number of passages, maintain the epithelial morphology (Figure 2a) . However, the combination of Kras activation and Pten loss in two distinct cell lines (MKPOSE-AdCre and MKPOSE2-AdCre) effectively induces EMT as demonstrated morphologically by the fibroblast-like appearance (Figure 2a) and molecularly, by downregulation of E-cadherin and upregulation of vimentin, two molecular markers typically associated with EMT 6 (Figure 2b ). Changes in vimentin and E-cadherin were minimal in MKOSE- AdCre and MPOSE-AdCre cells, reinforcing that simultaneous activation of the two pathways may synergistically induce EMT.
Together, these findings demonstrate that OSE transformation can be induced in vitro by Pten loss, but not oncogenic Kras and that the combination of these two pathways is synergistic for cell proliferation, transformation and EMT.
Tumor-derived cell lines maintain the phenotype of the originating tumor To further explore the effect of oncogenic Kras activation in conjunction with Pten deletion on EMT in vivo, we used our previously described MUC1KrasPten (Cre-loxP) conditional triple transgenic mice. 27 The MUC1KrasPten mice progress to human MUC1-expressing orthotopic ovarian tumors, following intrabursal injection of AdCre. At late stages the tumors spread outside of the ovaries and into the peritoneal cavity, mirroring the human disease. 27 Owing to isolating tumors tissue from one large primary ovarian tumor and a smaller tumor implant from one of the hepatic lobes of the same tumor-bearing mouse, we generated stable cancer cell lines MKP-T and MKP-Liver, respectively ( Figure 3a ). When reintroduced in the peritoneal cavity of healthy syngeneic mice the MKP-T cells grow as a single, large, localized tumor (similarly to the originating tumor), with no ascites (Figure 3b ). In contrast, the MKP-Liver cells (derived from a locoregional implant) form tumors throughout the peritoneal cavity and on the upper abdomen ( Figure 3c ). Furthermore, intraperitoneally (IP) injection of MKP-Liver cells also triggers lung metastases, suggesting that in addition to loco-regional spread, these cells also have the capacity for hematogenous metastasis ( Figure 3c ).
Tumor tissue from one of the lung metastases was used to generate the MKP-Lung cell line ( Figure 3d ). When injected IP in syngeneic mice, the MKP-Lung cells develop as IP tumors with lung metastases, in each of the recipient mice (Figure 3d ), suggesting that their molecular programming consistently leads to loco-regional plus hematogenous spread, mirroring stage IV human disease.
In line with the aggressive behavior in vivo, the most rapidly dividing MKP-T and MKP-Lung cells also show morphological (Figure 4a ) and molecular signs of EMT with high vimentin and low E-cadherin (Figure 4b) . Furthermore, MKP-T cells show loss of heterozygosity at the Kras locus (Kras LOH) (Figure 4c ) and have highest pMEK levels ( Figure 4d) .
In MKP-Liver cells derived from a loco-regional (liver) implant, E-cadherin is expressed at low levels as cytokeratin 7 remains high and vimentin upregulation has not occurred yet, suggesting a partial EMT, and explaining their potential for loco-regional dissemination. In line with their ability for systemic metastasis and aggressive growth, the MKP-Lung cells are clearly positive for EMT (with increased vimentin, loss of E-cadherin and cytokeratin) and have an accelerated doubling time in vitro and in vivo.
Overall, these in vivo experiments with new ovarian cancer cell lines derived from tumor implants with different anatomical locations demonstrate that similarly to patients, mice with orthotopic tumors show high degree of intra-tumor heterogeneity, and that cells from various locations reproduce the tumor (Figure 5c ). When BEZ235 and AZD6244 were used in combination, the overall inhibitory effect on MUC1 expression was preserved, although the drop in MUC1 was less pronounced than for BEZ235 alone, likely due to the counteracting effect from AZD6244 (Figure 5c ).
Furthermore, we tested the effect of AZD6244 on MUC1 expression in MKP-T cells (clone 2F8) with Kras LOH and high pMek levels. MUC1 levels significantly increase upon treatment with AZD6244 (Figure 5d ). The effect is largely reversed following drug withdrawal, although the frequency of MUC1 positive cells remained higher among treated cells compared to cells that were never exposed to the inhibitor, 7 days post treatment.
The pathway-specific effects on MUC1 were mirrored in two human ovarian cancer cell lines (A2780 and TOV21G), with defined PTEN and KRAS mutations. 30 The A2780 carry PTEN deletion and have high baseline MUC1. Exposure to BEZ235 triggers dose- Collectively, these results from mouse and human ovarian cancer cell lines demonstrate that the oncogenic Kras activation and Pten deletion inversely modulate MUC1 expression in ovarian cancer.
Gene signature of EMT associates with decreased overall survival in ovarian cancer patients The ovarian cancer models here recapitulate EMT in vitro and in vivo. To explore gene expression changes associated with this phenotype, we performed whole genome microarray expression analysis using MouseWG-6 v2.0 Expression BeadChip (Illumina, Inc., San Diego, CA, USA). Unsupervised cluster analysis shows that MKPOSE-AdCre, MKP-T and MKPOSE-Lung (all with mesenchymal appearance, aggressive cell proliferation and positive for EMT molecular markers) cluster together, separate from epithelial MKPOSE and MKPOSE-EV cells and MKP-Liver cells with partial EMT, suggesting a genotypic and phenotypic equivalence (Figure 6a) .
We identified differentially expressed (DE) genes (qo0.001), using the following four comparisons: MKPOSE-EV versus (vs) MKPOSE-AdCre (n = 455 DE genes), MKP-T vs MKP-Liver (n = 931 DE genes), MKP-T vs MKP-Lung (n = 114 DE genes) and MKP-Liver vs MKP-Lung (n = 694 DE genes). All genes are listed in Supplementary Table 1 Table 3) .
Given the aggressive in vivo behavior in preclinical models of cells positive for EMT, we postulated next that the common genes identified above (n = 121) may also identify tumors with increased aggressive behavior in ovarian cancer patients. To test for this, we applied the murine gene signature to the ovarian cancer The Cancer Genome Atlas (TCGA) microarray dataset of 542 patients. Of the 121 genes generated from our microarray approach, only 108 human genes could be retrieved from the TCGA dataset, due to gene filtering. The resulting heatmap using n = 108 human genes revealed one patient cluster (Figure 6d ) with gene upregulations (cluster 1, red accolades) similarly found in mouse cells with EMT (MKP-T, MKP-Lung and MKPOSE-AdCre). Genes upregulated in patients (Figure 6d, cluster 1 ) and EMT+ murine cell lines (Figure 6c , arrowheads) are shown in Supplementary Table 4. In line with our hypothesis, patients in cluster 1 show a modest but significant (P = 0.04) decrease in survival compared to the remaining patients.
Overall, these results demonstrate that the EMT-related gene signature obtained from our in vivo and in vitro preclinical studies reveal similar gene expression changes in patients with more aggressive ovarian tumors and decreased survival.
DISCUSSION
EMT in ovarian cancer has been difficult to reproduce in vivo in models that mimic the human disease. This is partly due to limited availability of ovarian cancer cell lines from human or mouse primary tumors. Until recently, only 26 human ovarian cancer cell lines from repositories like ATCC and ECACC have been publically 
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MUC1, Kras, Pten and EMT in ovarian cancer L Zhang et al primary or recurrent ovarian cancer is even more limited, with OSE-derived ID8 and IG10 cells with no well-defined mutations being predominantly used. [32] [33] [34] We report here a highly versatile collection of novel mouse OSE-derived cell lines featuring a unique combination of conditional or constitutive mutations in Kras, Pten or both. Although ovarian tumors may originate, at least in part in the tubal epithelia, our novel cell lines could further support the emerging view that tumors sharing specific genomic traits could be studied together, regardless of the cell/organ of origin. 35, 36 Using cells from genetically engineered mice, we demonstrate contrasting roles for Kras and Pten on cell proliferation, cellular transformation and MUC1 expression. Most importantly, using in vivo orthotopic tumor models we generated several additional tumor-derived cell lines that mirror the phenotype of the originating tumor. Moreover, the MKP-Lung cells that consistently metastasize to the lungs upon IP injection, establish the first immune competent in vivo model for distant hematogenous spread in ovarian cancer.
Our recently reported triple transgenic orthotopic mouse model demonstrates that when conditional oncogenic Kras (LSL-Kras G12D/+ ) and Pten deletion (Pten loxP/loxP ) are simultaneously triggered in OSE cells, the mice progress to human MUC1 overexpressing ovarian tumors. 27 However, these studies do not address the individual contributions of Kras and Pten to MUC1 expression. Here, we report that conditional activation of oncogenic Kras leads to diminished-cell surface MUC1 expression and pathway inhibition with AZD6244 leads to dose-dependent increase in MUC1 expression. Potential consequences of these findings are twofold: first, MUC1 acts as an oncogene (reviewed in 37 ) and any molecular events leading to its upregulation may provide cells during treatment with AZD6244 additional MUC1-induced survival benefit. Although MUC1 protein levels return upon drug withdrawal, reversal is not complete and selection of MUC1-high clones with survival advantage may be possible. Second, understanding AZD6244-induced effect on MUC1 upregulation can impact the design of treatments in combination with MUC1 immune therapies. MUC1 is a tumorassociated antigen expressed by virtually all adenocarcinomas. MUC1 overexpression initiates EMT in pancreatic cancer via increased interactions with b-catenin, and can modulate transcription of genes downstream of Erk in breast cancer. 38, 39 Different types of adenocarcinomas are currently tested for response to AZD6244 (Selumetinib) in clinical trials. [40] [41] [42] In light of our results, it would be important to determine if and how soluble, tumorderived MUC1 levels change (as determined in the clinic by the CA15-3 test, largely expected to regress during tumor involution) in patients treated with Mek/Erk inhibitors, and to determine influences of these changes on de novo MUC1-specific antibody and/or cellular responses. Most importantly, we postulate that MUC1 vaccines given soon after AZD6244 administration may show synergistic anti-tumor effects, due to higher MUC1-expressing targets. In contrast to Kras activation, deletion of Pten (triggering PI3K activation and increased pAkt levels) leads to MUC1 upregulation as the pathway inhibition with BEZ235 reverses the effect. Following a similar syllogism, we argue that combination therapies that would include MUC1 vaccines need to explore the correct timing in order to avoid low-protein levels in the target tumor cells.
Based on its pro-migration and pro-adhesion properties, we expected MUC1 to be overexpressed in cells with confirmed morphological and molecular EMT characteristics. In line with this hypothesis, epithelial-looking cells (like MKOSE, MPOSE or MKPOSE) express intermediate MUC1 levels and MUC1 was upregulated during EMT in vitro (MKPOSE-AdCre) and in vivo (MKP-Lung). Nevertheless, the mesenchymal-looking MKP-T cells have low MUC1, although this may be due to Kras LOH which likely hindered MUC1 increase.
In vivo selection of MKP-Lung tumor cells represents the first capture of distant metastasis and EMT in vivo in an ovarian cancer model. Remarkably, the MKP-Lung cells consistently follow the same pattern of migration to the lung post IP injection, suggesting an imprinted ability for hematogenous spread, a measurement of aggressive in vivo biology, and offering an unprecedented opportunity to profile genome-wide gene expression changes associated with EMT and metastasis in ovarian cancer. To test translatability of our findings to the human disease, we queried the TCGA and postulated that some of genes associated with EMT could be used as negative prognostic indicators in patients with ovarian cancer. Because the TCGA dataset contains almost exclusively patients with late stage tumors (and thus impeding comparisons according to disease stage), we focused on correlations of gene expression and overall survival. Patients with gene expression changes similar to those found in the EMT positive murine cell lines survived significantly less than the remaining patients. Further refinement of this gene list to identify tumors with aggressive biology is currently ongoing.
In summary, we have generated new ovarian cancer preclinical models using a series of cell lines with versatile mutations and different in vitro and in vivo tumor phenotypes. These models demonstrate distinct roles of Kras and Pten in ovarian cancer biology and can serve a wide range of applications, from screening new Kras and/ or Pten inhibitors, to exploring EMT induction in vivo and in vitro. In addition, our findings open unparalleled opportunities for further studies on the crosstalk between oncogenic MUC1, Kras and Pten tumor suppressor. As MUC1 is overexpressed in several other solid tumor types driven by Kras and/or Pten (like pancreas, lung, colon etc.), 43 these results impact future research in ovarian as well as non-ovarian adenocarcinomas and can guide future combination therapies with small drug inhibitors and MUC1 vaccines.
MATERIALS AND METHODS
Generation of ovarian cell lines from tumor tissues and OSE
MUC1KrasPten triple transgenic mice were injected with AdCre under the bursa of the left ovary and tumors were recovered after 8-10 weeks, as previously described. 27 Fresh tumor tissue was collected at necropsy, cut into 3-5 mm pieces, then digested with 0.1% Trypsin, 0.02% ethylenediaminetetraacetic acid (Gibco, Grand Island, NY, USA) at 37°C for 2 h. Recovered cells were cultured in Dulbecco's Modified Eagle Medium (Corning Cellgro, Manassas, VA, USA), supplemented with 10% fetal bovine serum (Cellgro), 10 000 U/l penicillin, 10 000 g/l streptomycin, 2 mM L-glutamine, 1% nonessential amino-acids, 1 mM sodium pyruvate, 0.1 mM 2-mercaptoethanol (all , MUC1) and Cre-loxP recombination post exposure to AdCre in vitro or in vivo.
For preparing growth curves of cell lines, cells were seeded in 24-well plates in triplicates and cell numbers were counted at five different time points.
Authentication of all OSE-derived cell lines described here was performed through genomic PCR for the presence of MUC1 and loxP cassettes at the (murine-specific) Kras and/or Pten loci before and after AdCre infection. Verification was performed for each experiment described herein. Surveillance for mycoplasma was performed periodically using mycoplasma PCR detection kit (Sigma).
In vitro cell transformation assay and in vivo tumor growth ) were suspended in phosphate buffered saline and injected intraperitoneally (ip) or subcutaneously into syngeneic (129 S4/SvJae) MUC1.Tg mice. Mice were sacrificed according to IACUC protocol for tumor burden.
Flow cytometry Histopathology
Tumor tissues were harvested and fixed in 10% buffered formalin (Fisher Scientific) for 24 h, stored in 70% ethanol for 2-3 days and subsequently embedded in paraffin. Four micron sections were cut and the gross histopathology was assessed by hematoxylin/eosin staining.
Microarray analysis
Total RNAs were isolated from the cell lines using AllPrep DNA/RNA/Protein Mini Kit (Qiagen). Each cell line had RNAs isolated from two different times (passages) in culture. RNA samples were sent to Genomics and Proteomics Core Laboratories, University of Pittsburgh for MouseWG-6 v2.0 Expression BeadChip (Illumina, Inc.) analysis. Raw data from scanned microarray chips were retrieved with background corrected using Illumina BeadStudio (as tab-delimited files) software. The lumi package in Bioconductor 44 was used to preprocess the raw data. For quality control, we kept probes with detection P-values o0.05 in at least one-third of all samples to ensure the remaining probes were truly detected. To minimize the effect of unwanted technical variation between RNA samples, the raw data was quantile normalized. In addition, the data was also log2 transformed to stabilize the variance. Heat map of sample correlation was plotted to identify problematic samples and batch effects.
After gene annotation, the Linear Model for Microarray Data in Bioconductor 45 was used to identify DE genes between two specified cell lines. We used Benjamini-Hochberg procedure to control for false discovery rate. Differentially expressed genes were loaded to Ingenuity Pathway Analyses for functional analysis. We also plotted the expression heatmap for a pre-specified list of genes that are associated with EMT.
To analytically characterize samples across the cell lines, we carried out unsupervised clustering. We performed feature filtering by removing genes with means or standard deviations under the median of all the genes. Based on the remaining 2619 expressed (with high-mean values) and informative (with large standard deviations) genes, hierarchical clustering with Ward linkage was applied. All statistical programming was implemented in R (code available upon request). The complete microarray data sets are available in the Gene Expression Omnibus database under accession number GSE69544.
The TCGA Ovarian Cancer mRNA expression data was retrieved from the Pittsburgh Genome Resource Repository (PGRR: http://www.pgrr.pitt.edu/ pgrr); 542 samples with available survival information were used. We plotted the heatmap for the selected 121 genes and a hierarchical clustering with Ward linkage was applied. A cluster of patients was identified from the heatmap and survival analysis was performed. Kaplan-Meier curve and log-rank test was used to compare survival distributions.
